|
NEWTOWN SQUARE, Pa., Nov. 27 /PRNewswire/ -- In its continued educational and research efforts for the advancement of homeopathy, Boiron Laboratories disputes an editorial comment published in The Lancet's Nov. 17, 2007 issue on the basis that its author has misinterpreted results of clinical trials on homeopathic medicines. (1-5)
The British medical journal features an editorial by Ben Goldacre on the "Benefits and Risks of Homeopathy." In his commentary, Goldacre suggests that the results from five large meta-analyses indicate that homeopathy produces no statistically significant benefit over placebo.
However, a thorough review of the studies' research evidence indicates positive principle conclusions in favor of homeopathy over placebo as quoted as follows:
1. The Kleijnen, et al(1) study states that "the evidence of clinical
trials is positive but not sufficient to draw any definite
conclusions."
2. The Boissel, et al(2) study reports that "[f]or 17 retained
comparisons, for each method used, the result is a p-value well below
.0001. This means that in at least one test, the null hypothesis (lack
of effect of homeopathy) must be rejected. ... The number of
significant results is not likely due to chance alone."
3. The Linde, et al(3) study concludes that "[t]he results of the
available randomized trials suggest that individualized homeopathy has
an effect over placebo."
4. The Cucherat, et al(4) study concludes that "[t]here is evidence that
homeopathic treatments are more effective than placebo."
5. The Shang, et al(5) study indicates that "21 (19 percent) homeopathic
trials and nine (8 percent) conventional medicine tests were of higher
quality. Most odds ratios indicated a beneficial effect of the
intervention. Heterogeneity of trial results was less pronounced for
homeopathy ... than conventional medicine .... This difference is
unlikely to be due to chance (p=0.011 by F test)."
Additionally, there is a sixth relevant meta-analysis(6) also published in The Lancet that supports positive results for homeopathy, but was not mentioned in Goldacre's commentary. The study authors concluded that "the results of our meta-analysis are not compatible with the hypothesis that the clinical effects of homeopathy are completely due to a placebo effect."
About Boiron: Boiron, world leader in homeopathy, is a $500 million public company with 3,800 employees in more than 60 countries. It produces more than 1,500 homeopathic medicines. For over 70 years, Boiron has been committed to funding scientific research and educating the public and healthcare professionals on homeopathic medicines. Boiron maintains the highest manufacturing standards, complying with U.S. Food and Drug Administration regulations, the Homeopathic Pharmacopoeia of the United States and drug Good Manufacturing Practices.
Read the full news here
|
Children represent the future, and ensuring their healthy growth and development ought to be a prime concern of all societies. Newborns are particularly vulnerable and children are vulnerable to malnutrition and infectious diseases, many of which can be effectively prevented or treated with homeopathy.
People who drink two or more sweetened soft drinks a week have a much higher risk of pancreatic cancer, an unusual but deadly cancer.